Glenmark Pharmaceuticals Ltd. (532296.BY) said Tuesday its generic drugs unit has received U.S. regulatory approval to manufacture and sell a generic version of Teva Women's Health Inc.'s Mircette contraceptive tablets.

The company plans to start shipping the generic version, called Viorele, immediately, it said in a statement.

Total sales of desogestrel and ethinyl estradiol and ethinyl estradiol combination, which is used to make Mircette, were about $98 million in 2011, the company said, citing IMS Health market research data.

-By Rumman Ahmed, Dow Jones Newswires; 91-9845104173; rumman.ahmed@dowjones.com